JOINN Laboratories China Purchases Instem’s Preclinical Software Suite
News Jan 30, 2013
Instem, a leading provider of IT solutions to the global early development healthcare market, announced that JOINN Laboratories (JOINN), one of China’s largest providers of preclinical services, has purchased the Provantis preclinical solution suite following a comprehensive competitive evaluation of vendors.
Established in 1995, JOINN provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services with a heightened focus on quality. JOINN supports clients from more than 20 provinces across China, Japan and Europe, and within the United States is providing international clients with technical consulting services for FDA drug registration.
• Comprehensive suite of integrated Provantis modules purchased for up to 200 users; including In-Life, Reproductive Toxicology, Pathology, Dispense, Clinical Pathology and Data Import
• JOINN to implement Provantis 9; the latest version of Instem’s market leading preclinical software solution
• Competitive evaluation conducted; Instem selected for established presence within China, combined with global market leadership
• Provantis offers JOINN compliance to national and western standards with dual language operation
• A range of professional services purchased to facilitate quicker, smoother implementation and faster return on investment
Dr. Yuxia Feng, President & CEO, JOINN commented “We were looking for a market leading solution to support our long term growth plans and we are confident that our investment in Provantis will help to deliver demonstrable efficiency improvements within our R&D facilities. We are looking forward to a long and successful partnership with Instem.”
Phil Reason, President & CEO Instem said “We are delighted to welcome JOINN to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the long term growth potential in what is already the third largest pharmaceutical market in the world.”
As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People’s Republic of China (PRC) is on pace to becoming the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC using on-site systems as well as their SaaS delivery model from a professionally managed data center based in Shanghai.
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE